Breaking News Instant updates and real-time market news.

AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

04:55
09/19/17
09/19
04:55
09/19/17
04:55

Aerie Pharmaceuticals management to meet with Needham

Meetings to be held in Canada September 18-19 hosted by Needham.

  • 19

    Sep

  • 25

    Sep

  • 28

    Feb

AERI Aerie Pharmaceuticals
$60.10

1.8 (3.09%)

07/03/17
ADAM
07/03/17
NO CHANGE
Target $65
ADAM
Buy
Aerie price target raised to $65 from $60 at Canaccord
Canaccord analyst Dewey Steadman said he remains confident in Aerie Pharmaceuticals' ability to launch Rhopressa as early at the first half of next year, noting that the company is preparing for an FDA advisory committee meeting that could happen before Thanksgiving. Steadman, who sees Rhopressa as a $500M product at its peak, also said he's confident in a potential Roclatan approval in 2019, stating that could be a $1B product. The analyst keeps a Buy rating on Aerie shares and raised his price target on the stock to $65 from $60.
08/17/17
ADAM
08/17/17
NO CHANGE
Target $65
ADAM
Buy
Aerie Pharmaceuticals manufacturing clearance removes overhang, says Canaccord
Canaccord analyst Dewey Steadman said the clearance of Aeri Pharmaceuticals' manufacturing clearance removes an overhang over the shares. He thinks the path is now cleared toward Rhopressa's February PDUFA and thinks now is one of the few opportunities ahead to invest in the shares ahead of the company's first potential approval. Steadman reiterated his Buy rating and $65 price target on Aeri Pharmaceuticals shares.
09/06/17
MZHO
09/06/17
INITIATION
Target $70
MZHO
Buy
Aerie Pharmaceuticals initiated with a Buy at Mizuho
Mizuho initiated Aerie Pharmaceuticals with a Buy and a $70 price target.
09/07/17
MZHO
09/07/17
INITIATION
Target $70
MZHO
Buy
Aerie Pharmaceuticals initiated with a Buy on glaucoma opportunity at Mizuho
As previously reported, Mizuho initiated Aeri Pharmaceuticals with a Buy and a $70 price target. Analyst Difei.Yang said Aeri is well positioned for FDA approvals of its two glaucoma drugs, Rhopressa and Roclatan in 2018-2019. If both are approved, he said the drugs would bring options for treating glaucoma with the first new mechanism of actions in nearly 20 years and sees potential for a buyout ahead of the FDA approvals in 2018

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.